YKYuya Kunisaki

Yuya Kunisaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuya Kunisaki has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Koichi Akashi

    Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    3 shared publications
  • Hiroyuki Mishima

    Department of Medical Technology, Kyushu University Hospital, Fukuoka, Japan

    2 shared publications
  • Ikumi Yamanaka

    Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

    2 shared publications
  • Shouichi Ohga

    Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    2 shared publications
  • Takahiro Maeda

    Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

    2 shared publications
  • Takuji Yamauchi

    Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

    2 shared publications

Latest Publications

  • Granulocyte collection by polymorphonuclear cell-targeting apheresis with medium-molecular-weight hydroxyethyl starch

    by Tomoko Henzan, Takuji Yamauchi, Ikumi Yamanaka, Teppei Sakoda, Yuichiro Semba, Masayasu Hayashi, Yoshikane Kikushige, Hiroyuki Mishima, Masataka Ishimura, Yuhki Koga, et al.

    Granulocyte transfusion (GTX) is a therapeutic option for patients with prolonged neutropenia suffering from severe infections. Efficient granulocyte collection by apheresis from donors requires clear separation of granulocytes from red blood cells (RBCs), and infusion of high-molecular-weight (MW) hydroxyethyl starch (HES) facilitates RBC sedimentation. Recent research has shown that apheresis with medium-MW HES may prevent adverse effects of high-MW HES on donors, but the rationale for collection with medium-MW HES has yet to be evaluated. To validate the use of medium-MW HES, we first performed experiments with whole blood samples to determine how efficiently high-, medium- and low-MW HES separated granulocytes from RBCs, and found that medium-MW HES was just as efficient as high-MW HES. We also reviewed clinical data of granulocyte apheresis at our institution to evaluate granulocyte yields. Retrospective analysis of granulocyte collection revealed that apheresis with medium-MW HES yielded sufficient granulocytes for GTX and that donor anemia reduced collection efficiency. These results collectively may help us to establish a safer method for apheresis targeting polymorphonuclear granulocytes as an alternative to high-MW HES.


  • Optimization of lymphapheresis for manufacturing autologous CAR-T cells

    by Ikumi Yamanaka, Takuji Yamauchi, Tomoko Henzan, Teppei Sakoda, Kyoko Miyamoto, Hiroyuki Mishima, Hiroaki Ono, Yuhki Koga, Yasuhiro Nakashima, Koji Kato, et al.

    Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have progressive diseases and receive medications that could reduce T cell counts. We conducted a retrospective study of clinical data from 28 patients who underwent lymphapheresis for CD19-directed CAR-T therapy with tisagenlecleucel to identify factors that could affect CD3+ lymphocyte yields. The numbers of CD3+ cells in peripheral blood were significantly correlated with CD3+ cell yields (correlation coefficient r = 0.84), which enabled us to estimate the volume of blood to process before apheresis. We also found that small cell ratio (SCR) at the apheresis site precisely reflected the proportion of lymphocytes, especially in patients without circulating blasts (coefficient of determination: r2 = 0.9). We were able to predict the CD3+ cell yield and prevent excessive apheresis by measuring pre-apheresis circulating CD3+ cell counts and monitoring SCR. Collectively, these results will help us to establish a strategy for optimization of lymphapheresis procedures for CAR-T cell production on a patient-by-patient basis.


  • Open Access

    Mitochondrial Protein Synthesis Is Essential for Terminal Differentiation of CD45– TER119–Erythroid and Lymphoid Progenitors

    by Kazuhito Gotoh, Yuya Kunisaki, Soichi Mizuguchi, Daiki Setoyama, Kentaro Hosokawa, Hisayuki Yao, Yuya Nakashima, Mikako Yagi, Takeshi Uchiumi, Yuichiro Semba, et al.


  • Open Access

    A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of Diffuse Large B-cell Lymphoma

    by Kohta Miyawaki, Koji Kato, Takeshi Sugio, Kensuke Sasaki, Hiroaki Miyoshi, Yuichiro Semba, Yoshikane Kikushige, Yasuo Mori, Yuya Kunisaki, Hiromi Iwasaki, et al.

    Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy with varying prognosis after the gold standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Several prognostic models have been established by focusing primarily on characteristics of lymphoma cells themselves including cell-of-origin, genomic alterations, and gene/protein expressions. However, the prognostic impact of lymphoma microenvironment and its association with characteristics of lymphoma cells are not fully understood. Using highly-sensitive transcriptome profiling of untreated DLBCL tissues, we here assess the clinical impact of lymphoma microenvironment on the clinical outcomes and pathophysiological, molecular signatures in DLBCL. The presence of normal germinal center (GC)-microenvironmental cells, including follicular T cells, macrophage/dendritic cells, and stromal cells, in lymphoma tissue indicates a positive therapeutic response. Our prognostic model, based on quantitation of transcripts from distinct GC-microenvironmental cell markers, clearly identified patients with graded prognosis independently of existing prognostic models. We observed increased incidences of genomic alterations and aberrant gene expression associated with poor prognosis in DLBCL tissues lacking GC-microenvironmental cells relative to those containing these cells. These data suggest that the loss of GC-associated microenvironmental signature dictates clinical outcomes of DLBCL patients reflecting the accumulation of “unfavorable” molecular signatures.


  • Pericytes in Bone Marrow

    by Yuya Kunisaki

    Bone marrow environments are composed of multiple cell types, most of which are thought to be derived from mesenchymal stem cells. In mouse bone marrow, stromal cells with CD45− Tie2− CD90− CD51+ CD105+ phenotype, Nestin-GFP+, CXCL12-abundant reticular (CAR) cells, PDGFRα+ Sca-1+ or CD51+ PDGFRα+, and Prx-1-derived CD45− Ter119− PDGFRα+ Sca-1+ populations select for MSC activity. There is evidence that these stromal cell populations display some significant overlap with each other and comprise important cellular constituents of the hematopoietic stem cell niche. Moreover, these mesenchymal cell populations share characteristics in their location as they all are found around bone marrow vessels (can be called “pericytes”). In this chapter, with reviewing the recent literatures, how the pericytes relate to physiological and pathological hematopoiesis is argued.


  • Influences of vascular niches on hematopoietic stem cell fate

    by Yuya Kunisaki, Paul S. Frenette

    The fate decision of hematopoietic stem cells (HSCs), quiescence, proliferation or differentiation, is uniquely determined by functionally specialized microenvironments defined as the HSC niches. However, whether quiescence and proliferation of HSCs are regulated by spatially distinct niches is unclear. Although various candidate stromal cells have been identified as potential niche cells, the spatial localization of quiescent HSCs in the bone marrow remains controversial. In our recent study, we have established whole-mount confocal immunofluorescence techniques, which allow us to precisely assess the localization of HSCs and their relationships with stromal structures. Furthermore, we have assessed the significance of these associations using a computational simulation. These novel analyses have revealed that quiescent HSCs are specifically associated with small caliber arterioles, which are predominantly distributed in the endosteal bone marrow while the associations with sinusoidal vessels or osteoblasts are not significant. Physical ablation of the arteriolar niche causes the shift of HSC localization to sinusoidal niches, where HSCs are switched into non-quiescent status. This new imaging analyses together with previous studies suggest the presence of spatially distinct vascular niches for quiescent and non-quiescent (proliferating) HSCs in the bone marrow.